Medtronic Plc
Exchange: NYSESector: HealthcareIndustry: Medical Devices
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery. About Medtronic Bold thinking. Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
Did you know?
Free cash flow has been growing at -2.1% annually.
Current Price
$78.30
-2.13%GoodMoat Value
$53.32
31.9% overvaluedProfile
Valuation (TTM)
Market Cap$100.38B
P/E21.76
EV$131.44B
P/B2.09
Shares Out1.28B
P/Sales2.83
Revenue$35.48B
EV/EBITDA12.87
Medtronic Plc (MDT) Stock Analysis
GoodMoat Analysis
Medtronic appears to have a moderate competitive moat but is currently priced at a significant premium to its estimated fair value. The stock's high valuation and modest growth profile present a challenging risk/reward scenario for a value investor.
Read full analysis
Medtronic Plc is a global leader in medical device technology, developing and manufacturing a wide range of products for chronic diseases across cardiac, neurological, and surgical fields. Using the GoodMoat framework, the company likely possesses a moat, scoring points for regulatory barriers, brand & culture, and niche dominance in complex, mission-critical devices. However, its moat score is likely moderate, not exceptional, as it faces intense competition and pricing pressure. Financially, the company shows stability with an 8.7% YoY revenue growth and a 3.19% dividend yield, but key quality indicators like ROE (9.6%) fall below the 15-20% high-quality threshold, and its growth trajectory is modest compared to high-growth medtech peers. The primary concern is valuation. At a price of $87.89, the stock trades at a P/E of 24.4x, which is high for its single-digit EPS growth profile. This is underscored by the GoodMoat Target of $53.32, suggesting the current price implies a deeply unfavourable margin of safety, likely exceeding -40%. Following the Decision Framework, while Medtronic may pass the initial Moat & Quality Gate, it fails the Valuation & Risk Gate decisively. The extreme premium to estimated intrinsic value and the high P/E for its growth rate are critical red flags. For a value investor, this signals an unfavourable setup, as the price offers no margin of safety and requires near-perfect future execution to justify.
Market Cap$100.38B
Current Price$78.30
P/E Ratio21.76
Forward P/E—
PEG Ratio-1.83
EPS$3.61
Book Value$37.46
P/B Ratio2.09
MDT Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use -2.1% FCF growth (CAGR)
Cash vs Debt
Net Debt: 26.3B
Revenue
30.6B
FY19
28.9B
FY20
30.1B
FY21
31.7B
FY22
31.2B
FY23
32.4B
FY24
33.5B
FY25
Net Income
4.6B
FY19
4.8B
FY20
3.6B
FY21
5.0B
FY22
3.8B
FY23
3.7B
FY24
4.7B
FY25
MDT 52-Week Range
$78.20
$103.74
50-Day MA: $87.58200-Day MA: $92.88
Did you know?
Free cash flow has been growing at -2.1% annually.
Medtronic Plc (MDT) Financial Summary
Medtronic Plc (MDT) is a Healthcare company in the Medical Devices industry, listed on NYSE. The stock currently trades at $78.30 with a market capitalization of $100.38B.
Key valuation metrics include a P/E ratio of 21.76, price-to-book ratio of 2.09, and EPS of $3.61. The company reports a profit margin of 13.0% and return on equity of 9.6%.
MDT Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $100.38B |
| P/E Ratio | 21.76 |
| EPS | $3.61 |
| P/B Ratio | 2.09 |
| P/S Ratio | 2.83 |
| EV/EBITDA | 12.87 |
| Dividend Yield | 3.58% |
| Profit Margin | 13.0% |
| Return on Equity | 9.6% |
| Debt/Equity | 0.59 |
MDT Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $30.56B | $4.63B |
| FY20 | $28.91B | $4.79B |
| FY21 | $30.12B | $3.61B |
| FY22 | $31.69B | $5.04B |
| FY23 | $31.23B | $3.76B |
| FY24 | $32.36B | $3.68B |
| FY25 | $33.54B | $4.66B |
Medtronic Plc (MDT) Valuation
Based on GoodMoat's DCF model, Medtronic Plc has a fair value estimate of $53.32. At the current price of $78.30, the stock appears 46.8% overvalued relative to our intrinsic value estimate.
MDT Quality Indicators
Medtronic Plc maintains a profit margin of 13.0% and an operating margin of 17.8%. Return on equity stands at 9.6%. The current ratio is 1.85. Debt-to-equity ratio is 0.59.
About Medtronic Plc
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery. About Medtronic Bold thinking. Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
MDT Free Cash Flow
Medtronic Plc generated $5.18B in trailing twelve-month free cash flow, representing an FCF yield of 5.17%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
MDT Shares Outstanding
Medtronic Plc has 1.28 billion shares outstanding at a share price of $78.30, giving it a market capitalization of $100.38B.
MDT Recent Insider Trades
Recent insider transactions at Medtronic Plc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| KIIL HARRY SKIP (EVP & President Cardiovascular) | SELL | 1,648 | $161273.28 |